DBVT vs ALKS vs PRGO vs SLRX vs SNGX

For growth investors, Perrigo Company plc (PRGO) is the stronger pick with -2.

8% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Alkermes plc (ALKS) offers the better valuation at 25. 3x trailing P/E, making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +64.

4%, compared to -100. 0% for Salarius Pharmaceuticals, Inc. (SLRX). Over 10 years, the gap is even starker: ALKS returned -4. 6% versus SLRX's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Alkermes plc (ALKS) is the lower-risk stock at 1.

06β versus Soligenix, Inc. 's 1. 97β — meaning SNGX is approximately 86% more volatile than ALKS relative to the S&P 500. On balance sheet safety, Perrigo Company plc (PRGO) carries a lower debt/equity ratio of 1% versus 36% for Soligenix, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Perrigo Company plc (PRGO) is pulling ahead at -2.

8% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: Soligenix, Inc. grew EPS 60. 7% year-over-year, compared to -1522. 7% for Salarius Pharmaceuticals, Inc.. Over a 3-year CAGR, ALKS leads at 9. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Alkermes plc (ALKS) is the more profitable company, earning 16.

4% net margin versus -33. 5% for Perrigo Company plc — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus -26. 4% for PRGO. At the gross margin level — before operating expenses — ALKS leads at 86. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for DBVT: 137.

7% to $46. 33.

In this comparison, PRGO (9.

9% yield) pays a dividend. DBVT, ALKS, SLRX, SNGX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Perrigo Company plc (PRGO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.

18), 9. 9% yield). Soligenix, Inc. (SNGX) carries a higher beta of 1. 97 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PRGO: -78. 5%, SNGX: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: DBVT is a mega-cap quality compounder stock; ALKS is a small-cap quality compounder stock; PRGO is a small-cap income-oriented stock; SLRX is a small-cap quality compounder stock; SNGX is a small-cap quality compounder stock. PRGO pays a dividend while DBVT, ALKS, SLRX, SNGX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.